Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bacterial Infections and Mycoses

  Free Subscription

Articles published in
Lancet
    November 2026
  1. VAN DER ZALM MM, Barday MA
    Empirical tuberculosis treatment in infants living with HIV: missed opportunities and ways to improve outcomes.
    Lancet. 2026;408:2044-2046.
    >> Share

    July 2026
  2. DEZZA FC, Pulido LB, Borreguero IB, Perez FD, et al
    Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTE): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.
    Lancet. 2026 Jul 9:S0140-6736(26)00760-9. doi: 10.1016/S0140-6736(26)00760.
    >> Share

    June 2026

  3. Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial.
    Lancet. 2026 Jun 17:S0140-6736(26)00761-0. doi: 10.1016/S0140-6736(26)00761.
    >> Share

  4. WESTGEEST AC, Fowler VG Jr
    Treating penicillin-susceptible Staphylococcus aureus bacteraemia: confusing the issue with facts.
    Lancet. 2026 Jun 17:S0140-6736(26)00857-3. doi: 10.1016/S0140-6736(26)00857.
    >> Share

    March 2026
  5. SAMARASEKERA U
    Claire Calderwood: integrated health screening for tuberculosis.
    Lancet. 2026;407:1135.
    >> Share

  6. OGA-OMENKA C, Rabvukwa A, Chijioke-Akaniro O, Mwirigi N, et al
    Understanding where people with tuberculosis seek care to serve them better.
    Lancet. 2026 Mar 20:S0140-6736(26)00543-X. doi: 10.1016/S0140-6736(26)00543.
    >> Share

    February 2026
  7. AGUDELO HIGUITA NI, Avanzi C, Henao-Martinez AF, Honap TP, et al
    Leprosy.
    Lancet. 2026;407:805-819.
    >> Share

  8. ERGONUL O, Kolsuz S, Figueroa JP
    Tetanus.
    Lancet. 2026;407:716-727.
    >> Share

    December 2025
  9. HUI D, Sahu S, Ditiu L, Marais BJ, et al
    Global tuberculosis response off track: urgent priorities to end the world's top infectious killer.
    Lancet. 2025 Dec 11:S0140-6736(25)02433-X. doi: 10.1016/S0140-6736(25)02433.
    >> Share

  10. LUCKEY A, Balasegaram M, Barbee LA, Batteiger TA, et al
    Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.
    Lancet. 2025 Dec 11:S0140-6736(25)01953-1. doi: 10.1016/S0140-6736(25)01953.
    >> Share

  11. LATEEF S
    Aid cuts hampering Nepal's tuberculosis care.
    Lancet. 2025 Dec 4:S0140-6736(25)02469-9. doi: 10.1016/S0140-6736(25)02469.
    >> Share

    October 2025
  12. BURDET C, Saidani N, Dupieux C, Lemaignen A, et al
    Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial.
    Lancet. 2025 Oct 17:S0140-6736(25)01624-1. doi: 10.1016/S0140-6736(25)01624.
    >> Share

  13. HENDRICK J, Raqib R, Noor Z, Faruque ASG, et al
    Shigellosis.
    Lancet. 2025;406:1508-1519.
    >> Share

    September 2025
  14. KUEHN R, Rahden P, Hussain HS, Karkey A, et al
    Enteric (typhoid and paratyphoid) fever.
    Lancet. 2025;406:1283-1294.
    >> Share

    August 2025
  15. DROBNIEWSKI F, Kon OM, Gonzalo X, Ashmi M, et al
    Why are we failing to rapidly diagnose tuberculosis in the UK?
    Lancet. 2025;406:908-909.
    >> Share

    July 2025
  16. ABUZERR S, Hamdan H, Charafeddine J
    Paediatric meningitis outbreak in Gaza amid health system collapse.
    Lancet. 2025 Jul 31:S0140-6736(25)01520-X. doi: 10.1016/S0140-6736(25)01520.
    >> Share

  17. MACIEL EL, Pablos-Mendez A, Abubakar I
    Undoing progress through sudden tuberculosis funding cuts.
    Lancet. 2025 Jul 3:S0140-6736(25)01328-5. doi: 10.1016/S0140-6736(25)01328.
    >> Share

  18. HALLETT TB, Menzies NA, Resch S, Pretorius C, et al
    The case for optimal investment in combating HIV, tuberculosis, and malaria: a global modelling study.
    Lancet. 2025 Jul 3:S0140-6736(25)00831-1. doi: 10.1016/S0140-6736(25)00831.
    >> Share

    June 2025
  19. HIRANI K, Rwebembera J, Webb R, Beaton A, et al
    Acute rheumatic fever.
    Lancet. 2025;405:2164-2178.
    >> Share

  20. AL ZAMEL AM, Saeed AA, Elmubarak M, Alsarraj MA, et al
    Sudan's tuberculosis response needs global support amid conflict.
    Lancet. 2025 Jun 2:S0140-6736(25)01119-5. doi: 10.1016/S0140-6736(25)01119.
    >> Share

    May 2025
  21. HABTAMU E, Harding-Esch EM, Greenland K, Wamyil-Mshelia T, et al
    Trachoma.
    Lancet. 2025;405:1865-1878.
    >> Share

  22. SUNDAR R, Nakayama I, Markar SR, Shitara K, et al
    Gastric cancer.
    Lancet. 2025 May 1:S0140-6736(25)00052-2. doi: 10.1016/S0140-6736(25)00052.
    >> Share

    April 2025
  23. ROSS JDC, Wilson J, Workowski KA, Taylor SN, et al
    Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.
    Lancet. 2025 Apr 11:S0140-6736(25)00628-2. doi: 10.1016/S0140-6736(25)00628.
    >> Share

  24. KLUGE HHP
    Tuberculosis: a threat to health security in the European region and the collective actions needed.
    Lancet. 2025 Apr 7:S0140-6736(25)00677-4. doi: 10.1016/S0140-6736(25)00677.
    >> Share

    March 2025
  25. DHEDA K, Perumal T, Fox GJ
    Asymptomatic tuberculosis: undetected and underestimated, but not unimportant.
    Lancet. 2025 Mar 21:S0140-6736(25)00555-0. doi: 10.1016/S0140-6736(25)00555.
    >> Share

  26. JERENE D, van Kalmthout K, Levy J, Alacapa J, et al
    Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials.
    Lancet. 2025 Mar 11:S0140-6736(24)02847-2. doi: 10.1016/S0140-6736(24)02847.
    >> Share

  27. MARX FM, Civan A
    Rethinking the benefits of digital adherence technologies for tuberculosis treatment.
    Lancet. 2025 Mar 11:S0140-6736(25)00199-0. doi: 10.1016/S0140-6736(25)00199.
    >> Share

  28. TROTTER C, Diallo K
    Another step towards defeating meningitis.
    Lancet. 2025 Mar 11:S0140-6736(25)00196-5. doi: 10.1016/S0140-6736(25)00196.
    >> Share

  29. DIALLO F, Haidara FC, Tapia MD, Dominguez Islas CP, et al
    Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, c
    Lancet. 2025 Mar 11:S0140-6736(25)00046-7. doi: 10.1016/S0140-6736(25)00046.
    >> Share

  30. TRAJMAN A, Campbell JR, Kunor T, Ruslami R, et al
    Tuberculosis.
    Lancet. 2025;405:850-866.
    >> Share

    February 2025
  31. ZUMLA A, Sahu S, Yeboah-Manu D, Goletti D, et al
    Breaking dependency: strengthening the global tuberculosis response in the face of USAID cuts.
    Lancet. 2025 Feb 26:S0140-6736(25)00335-6. doi: 10.1016/S0140-6736(25)00335.
    >> Share

  32. SABAT R, Alavi A, Wolk K, Wortsman X, et al
    Hidradenitis suppurativa.
    Lancet. 2025;405:420-438.
    >> Share

    January 2025
  33. MACESIC N, Uhlemann AC, Peleg AY
    Multidrug-resistant Gram-negative bacterial infections.
    Lancet. 2025;405:257-272.
    >> Share

    October 2024
  34. BHARGAVA A, Bhargava M, Velayutham B, Benedetti A, et al
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial - Authors' reply.
    Lancet. 2024;404:1524.
    >> Share

  35. ZHANG K, Xu Y, Hu Y, Chen X, et al
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1523-1524.
    >> Share

  36. BUSANG J, Khan P
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1522-1523.
    >> Share

  37. RICKMAN HM, Yates TA
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1522.
    >> Share

  38. KAUR JABINDA M
    Nutritional supplementation for tuberculosis prevention: the RATIONS trial.
    Lancet. 2024;404:1521-1522.
    >> Share

  39. QADRI F, Khanam F, Zhang Y, Biswas PK, et al
    5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
    Lancet. 2024;404:1419-1429.
    >> Share

  40. BHATTARAI MD
    Utilising available isoniazid-resistance tests in new patients.
    Lancet. 2024;404:1403.
    >> Share

  41. AL-MAMUN F, Mamun MA, Roy N
    Long-term efficacy and public health implications of the Vi-tetanus toxoid conjugate vaccine in Bangladeshi children.
    Lancet. 2024;404:1378-1379.
    >> Share

    September 2024
  42. KHAN M
    "The final warning sign": XDR typhoid.
    Lancet. 2024;404:1182-1183.
    >> Share

  43. VAN RHIJN N, Arikan-Akdagli S, Beardsley J, Bongomin F, et al
    Beyond bacteria: the growing threat of antifungal resistance.
    Lancet. 2024;404:1017-1018.
    >> Share


  44. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.
    Lancet. 2024 Sep 13:S0140-6736(24)01867-1. doi: 10.1016/S0140-6736(24)01867.
    >> Share

  45. HIRATE T, Kanda K, Ohshima Y, Shinoda K, et al
    Congenital syphilis in a 2-month-old infant during Japanese outbreak.
    Lancet. 2024;404:971.
    >> Share

    August 2024
  46. NEUZIL KM, Patel PD, Ndeketa L, Laurens MB, et al
    Efficacy of typhoid conjugate vaccine in Malawian children - Authors' reply.
    Lancet. 2024;404:748.
    >> Share

  47. OBARO S
    Efficacy of typhoid conjugate vaccine in Malawian children.
    Lancet. 2024;404:747-748.
    >> Share

    July 2024
  48. LI M, Kim JB, Sastry BKS, Chen M, et al
    Infective endocarditis.
    Lancet. 2024;404:377-392.
    >> Share

    June 2024
  49. HYDE L
    Mobile screening for Ukraine's wartime tuberculosis epidemic.
    Lancet. 2024;403:2771.
    >> Share

  50. MCCANN N, Vicentine MP, Pollard AJ
    Towards paratyphoid control: the vital role of the challenge model.
    Lancet. 2024;403:2780-2781.
    >> Share

  51. CRENNER C
    Ulcers, stress, and the discovery of Helicobacter pylori.
    Lancet. 2024;403:2586-2587.
    >> Share

  52. WHITE NJ
    Death from diphtheria.
    Lancet. 2024;403:2590-2591.
    >> Share

  53. LIOU JM, Malfertheiner P, Smith SI, El-Omar EM, et al
    40 years after the discovery of Helicobacter pylori: towards elimination of H pylori for gastric cancer prevention.
    Lancet. 2024;403:2570-2572.
    >> Share

  54. ALMADI MA, Lu Y, Alali AA, Barkun AN, et al
    Peptic ulcer disease.
    Lancet. 2024 Jun 14:S0140-6736(24)00155-7. doi: 10.1016/S0140-6736(24)00155.
    >> Share

  55. MARIONI G, Franz L, Incognito A, Bitonti S, et al
    Bilateral simultaneous cochlear implant in an adult with anacusis due to bacterial meningitis.
    Lancet. 2024;403:2533.
    >> Share

  56. MOLINELLI E, Simonetti O
    Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa.
    Lancet. 2024;403:2457-2459.
    >> Share

  57. ASHINZE P, Mafua N, Obafemi E
    Nigeria rolls out novel meningitis vaccine.
    Lancet. 2024;403:2373.
    >> Share

    May 2024
  58. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    >> Share

  59. LEWNARD JA, Charani E, Gleason A, Hsu LY, et al
    Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis.
    Lancet. 2024 May 20:S0140-6736(24)00862-6. doi: 10.1016/S0140-6736(24)00862.
    >> Share

  60. OKEKE IN, de Kraker MEA, Van Boeckel TP, Kumar CK, et al
    The scope of the antimicrobial resistance challenge.
    Lancet. 2024 May 20:S0140-6736(24)00876-6. doi: 10.1016/S0140-6736(24)00876.
    >> Share

  61. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    >> Share

  62. DE OLIVEIRA FRANCO A, Uberti Dos Santos V, von Ameln Lovison O, Zavascki AP, et al
    Invasive liver abscess syndrome with central nervous system involvement caused by hypermucoviscous Klebsiella pneumoniae: positive string test.
    Lancet. 2024;403:2257-2258.
    >> Share

    March 2024
  63. RAQIB R
    Bivalent conjugate vaccines for typhoid and paratyphoid fever.
    Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
    >> Share

  64. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    >> Share

  65. BURKI T
    Pivotal tuberculosis vaccine trial begins.
    Lancet. 2024;403:1125.
    >> Share

  66. BHARGAVA A, Bhargava M, Pai M
    Tuberculosis: a biosocial problem that requires biosocial solutions.
    Lancet. 2024 Mar 20:S0140-6736(24)00489-6. doi: 10.1016/S0140-6736(24)00489.
    >> Share

  67. BURKI T
    The great cholera vaccine shortage.
    Lancet. 2024;403:891-892.
    >> Share

  68. SUBBARAMAN R, Fielding K
    Putting technology to the test in tuberculosis care.
    Lancet. 2024;403:878-879.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016